RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3952-3962

  Alvarez, Rene ^a   Elbashir, Sayda ^a   Borland, Todd ^a   Toudjarska, Ivanka ^a   Hadwiger, Philipp ^b   John, Mathias ^b   Roehl, Ingo ^b   Morskaya, Svetlana Shulga ^a   Martinello, Rick ^c   Kahn, Jeffrey ^c   Van Ranst, Mark ^d   Tripp, Ralph A ^e   DeVincenzo, John P ^f   Pandey, Rajendra ^a   Maier, Martin ^a   Nechev, Lubomir ^a   Manoharan, Muthiah ^a   Kotelianski, Victor ^a   Meyers, Rachel ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

^b Roche Kulmbach   (Germany)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF GEORGIA   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALN RSV 01; ALPHA INTERFERON; ANTIVIRUS AGENT; COMPLEMENTARY DNA; MESSENGER RNA; NUCLEOCAPSID PROTEIN; TRANSFER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; IC 50; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA INTERFERENCE; SINGLE DRUG DOSE; VIRUS GENE; VIRUS INHIBITION; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; GENOTYPE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MICE; NUCLEOCAPSID; PHYLOGENY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349147840     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00014-09     Document Type: Article

References (86)

1. Altschul, S. F., and E. V. Koonin. 1998. Iterated profile searches with PSIBLAST- a tool for discovery in protein databases. Trends Biochem. Sci. 23:444-447.
2. Anonymous. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:26-28.
3. Anonymous. 2003. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory sycytial virus infections. Pediatrics 112:1442-1446.
4. Arbuthnot, P., S. Carmona, and A. Ely. 2005. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 25:9-15. (Pubitemid 40298239)
5. Billings, J. L., M. I. Hertz, and C. H. Wendt. 2001. Community respiratory virus infections following lung transplantation. Transpl. Infect. Dis. 3:138-148.
6. Bitko, V., A. Musiyenko, O. Shulyayeva, and S. Barik. 2005. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11:50-55.
7. Bosher, J. M., and M. Labouesse. 2000. RNA interference: genetic wand and genetic watchdog. Nat. Cell Biol. 2:E31-E36.
8. Boyce, T. G., B. G. Mellen, E. F. Mitchel, Jr., P. F. Wright, and M. R. Griffin. 2000. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J. Pediatr. 137:865-870.
9. Carmichael, G. G. 2002. Medicine: silencing viruses with RNA. Nature 418:379-380.
10. Centers for Disease Control and Prevention. 2002. Respiratory syncytial virus activity-United States, 2000-01 season. MMWR Morb. Mortal. Wkly. Rep. 51:26-28.
11. Couch, R. B., J. A. Englund, and E. Whimbey. 1997. Respiratory viral infections in immunocompetent and immunocompromised persons. Am. J. Med. 102:2-9.
12. Cramer, H. 2005. Antisense approaches for inhibiting respiratory syncytial virus. Expert Opin. Biol. Ther. 5:207-220.
13. de Fougerolles, A., H. P. Vornlocher, J. Maraganore, and J. Lieberman. 2007. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6:443-453.
14. DeVincenzo, J., J. E. Cehelsky, R. Alvarez, S. Elbashir, J. Harborth, I. Toudjarska, L. Nechev, V. Murugaiah, A. Van Vliet, A. K. Vaishnaw, and R. Meyers. 2008. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir. Res. 77:225-231.
15. Douglas, J. L., M. L. Panis, E. Ho, K. Y. Lin, S. H. Krawczyk, D. M. Grant, R. Cai, S. Swaminathan, X. Chen, and T. Cihlar. 2005. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 49:2460-2466.
16. Douglas, J. L., M. L. Panis, E. Ho, K. Y. Lin, S. H. Krawczyk, D. M. Grant, R. Cai, S. Swaminathan, and T. Cihlar. 2003. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 77:5054-5064.
17. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
18. Falsey, A. R. 1998. Respiratory syncytial virus infection in older persons. Vaccine 16:1775-1778. (Pubitemid 28545110)
19. Falsey, A. R., P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759.
20. Falsey, A. R., and E. E. Walsh. 2000. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13:371-384.
21. Fixler, D. E. 1996. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr. Cardiol. 17:163-168.
22. Gazumyan, A., B. Mitsner, and G. A. Ellestad. 2000. Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation. Curr. Pharm. Des. 6:525-546.
23. Ge, Q., M. T. McManus, T. Nguyen, C. H. Shen, P. A. Sharp, H. N. Eisen, and J. Chen. 2003. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100:2718-2723.
24. Giladi, H., M. Ketzinel-Gilad, L. Rivkin, Y. Felig, O. Nussbaum, and E. Galun. 2003. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 8:769-776.
25. Glezen, P., and F. W. Denny. 1973. Epidemiology of acute lower respiratory disease in children. N. Engl. J. Med. 288:498-505.
26. Gower, T. L., and B. S. Graham. 2001. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 45:1231-1237.
27. Groothuis, J. R., E. A. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, et al. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
28. Guney, C., A. Kubar, M. Yapar, A. B. Besirbellioglu, and L. Doganci. 2004. An outbreak of respiratory infection due to respiratory syncytial virus subgroup B in Ankara, Turkey. Jpn. J. Infect. Dis. 57:178-180.
29. Hall, C. B., E. E. Walsh, K. C. Schnabel, C. E. Long, K. M. McConnochie, S. W. Hildreth, and L. J. Anderson. 1990. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 162:1283-1290.
30. Hannon, G. J. 2002. RNA interference. Nature 418:244-251.
31. He, M. L., B. Zheng, Y. Peng, J. S. Peiris, L. L. Poon, K. Y. Yuen, M. C. Lin, H. F. Kung, and Y. Guan. 2003. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290:2665-2666. (Pubitemid 37475592)
32. Hornung, V., M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, S. Endres, and G. Hartmann. 2005. Sequence-specific potent induction of IFNalpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-270.
33. Hruska, J. F., P. E. Morrow, S. C. Suffin, and R. G. Douglas, Jr. 1982. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob. Agents Chemother. 21:125-130.
34. Jackson, A. L., J. Burchard, J. Schelter, B. N. Chau, M. Cleary, L. Lim, and P. S. Linsley. 2006. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-1187.
35. Johnson, S., S. D. Griego, D. S. Pfarr, M. L. Doyle, R. Woods, D. Carlin, G. A. Prince, S. Koenig, J. F. Young, and S. B. Dillon. 1999. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J. Infect. Dis. 180:35-40.
36. Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S. C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, and J. F. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
37. Judge, A. D., V. Sood, J. R. Shaw, D. Fang, K. McClintock, and I. Mac- Lachlan. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-462.
38. Kachko, A. V., A. V. Ivanova, E. V. Protopopova, V. Netesov, and V. B. Loktev. 2006. Inhibition of West Nile virus replication by short interfering RNAs. Dokl. Biochem. Biophys. 410:260-262.
39. Kalina, W. V., and L. J. Gershwin. 2004. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin. Dev. Immunol. 11:113-119.
40. Kleinman, M. E., K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J. Z. Baffi, R. J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, B. Appukuttan, D. Gibbs, Z. Yang, K. Kariko, B. K. Ambati, T. A. Wilgus, L. A. DiPietro, E. Sakurai, K. Zhang, J. R. Smith, E. W. Taylor, and J. Ambati. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597.
41. Kuroiwa, Y., K. Nagai, L. Okita, and H. Tsutsumi. 2004. Genetic variability and molecular epidemiology of respiratory syncytial virus subgroup A strains in Japan determined by heteroduplex mobility assay. J. Clin. Microbiol. 42:2048-2053.
42. Lai, S. H., D. A. Stein, A. Guerrero-Plata, S. L. Liao, T. Ivanciuc, C. Hong, P. L. Iversen, A. Casola, and R. P. Garofalo. 2008. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. 16:1120-1128.
43. Law, B. J., E. E. Wang, N. MacDonald, J. McDonald, S. Dobson, F. Boucher, J. Langley, J. Robinson, I. Mitchell, and D. Stephens. 1997. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database. Pediatrics 99:E7.
44. Leader, S., and K. Kohlhase. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr. Infect. Dis. J. 21:629-632.
45. Martinello, R. A., M. D. Chen, C. Weibel, and J. S. Kahn. 2002. Correlation between respiratory syncytial virus genotype and severity of illness. J. Infect. Dis. 186:839-842.
46. McConnochie, K. M., C. B. Hall, E. E. Walsh, and K. J. Roghmann. 1990. Variation in severity of respiratory syncytial virus infections with subtype. J. Pediatr. 117:52-62. (Pubitemid 20217493)
47. McCown, M., M. S. Diamond, and A. Pekosz. 2003. The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313:514-524. (Pubitemid 37045358)
48. Meissner, H. C., M. B. Rennels, S. S. Long, and L. K. Pickering. 2004. Immunoprophylaxis with RespiGam. Pediatrics 113:629.
49. Mufson, M. A., B. Akerlind-Stopner, C. Orvell, R. B. Belshe, and E. Norrby. 1991. A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988. J. Clin. Microbiol. 29:162-165.
50. Ogra, P. L. 2004. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr. Respir. Rev. 5(Suppl. A):S119-S126.
51. Peebles, R. S., Jr. 2004. Viral infections, atopy, and asthma: is there a causal relationship? J. Allergy Clin. Immunol. 113:S15-S18.
52. Player, M. R., D. L. Barnard, and P. F. Torrence. 1998. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. USA 95:8874-8879.
53. Pruitt, K. D., T. Tatusova, and D. R. Maglott. 2005. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 33:D501-D504.
54. Psarras, S., N. G. Papadopoulos, and S. L. Johnston. 2004. Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezing. Paediatr. Respir. Rev. 5(Suppl. A):S179-S184.
55. Razinkov, V., A. Gazumyan, A. Nikitenko, G. Ellestad, and G. Krishnamurthy. 2001. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. 8:645-659.
56. Razinkov, V., C. Huntley, G. Ellestad, and G. Krishnamurthy. 2002. RSV entry inhibitors block F-protein mediated fusion with model membranes. Antivir. Res. 55:189-200.
57. Robbins, M., A. Judge, E. Ambegia, C. Choi, E. Yaworski, L. Palmer, K. McClintock, and I. MacLachlan. 2008. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19:991-999.
58. Robbins, M., A. Judge, L. Liang, K. McClintock, E. Yaworski, and I. Mac- Lachlan. 2007. 2′-O-Methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15:1663-1669.
59. Saksela, K. 2003. Human viruses under attack by small inhibitory RNA. Trends Microbiol. 11:345-347. (Pubitemid 37289273)
60. Schlee, M., V. Hornung, and G. Hartmann. 2006. siRNA and isRNA: two edges of one sword. Mol. Ther. 14:463-470.
61. Shay, D. K., R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446.
62. Simoes, E. A. 1999. Respiratory syncytial virus infection. Lancet 354:847-852.
63. Sioud, M. 2005. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348:1079-1090.
64. Staat, M. A. 2002. Respiratory syncytial virus infections in children. Semin. Respir. Infect. 17:15-20.
65. Stein, D. A., and P. Y. Shi. 2008. Nucleic acid-based inhibition of flavivirus infections. Front Biosci. 13:1385-1395.
66. Stevens, T. P., and C. B. Hall. 2004. Controversies in palivizumab use. Pediatr. Infect. Dis. J. 23:1051-1052.
67. Sullender, W. M. 2000. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microbiol. Rev. 13:1-15.
68. Sullender, W. M., L. Sun, and L. J. Anderson. 1993. Analysis of respiratory syncytial virus genetic variability with amplified cDNAs. J. Clin. Microbiol. 31:1224-1231.
69. Taylor, J. A., and N. V. Naoumov. 2005. The potential of RNA interference as a tool in the management of viral hepatitis. J. Hepatol. 42:139-144.
70. Tompkins, S. M., C. Y. Lo, T. M. Tumpey, and S. L. Epstein. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101:8682-8686.
71. Torrence, P. F. 1999. 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection. Curr. Opin. Mol. Ther. 1:307-315.
72. Tripp, R. A., D. Moore, L. Jones, W. Sullender, J. Winter, and L. J. Anderson. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cyto- kines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
73. Ventre, K., and A. Randolph. 2004. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. CD000181.
74. Walsh, E. E., K. M. McConnochie, C. E. Long, and C. B. Hall. 1997. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 175:814-820.
75. Wang, Q. C., Q. H. Nie, and Z. H. Feng. 2003. RNA interference: antiviral weapon and beyond. World J. Gastroenterol. 9:1657-1661.
76. Wang, Z., L. Ren, X. Zhao, T. Hung, A. Meng, J. Wang, and Y. G. Chen. 2004. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. 78:7523-7527. (Pubitemid 38915898)
77. Wu, C. J., H. W. Huang, C. Y. Liu, C. F. Hong, and Y. L. Chan. 2005. Inhibition of SARS-CoV replication by siRNA. Antivir. Res. 65:45-48.
78. Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon. 1995. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:543-550.
79. Xie, Y. Y., X. D. Zhao, L. P. Jiang, H. L. Liu, L. J. Wang, P. Fang, K. L. Shen, Z. D. Xie, Y. P. Wu, and X. Q. Yang. 2006. Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme). Antivir. Res. 71:31-41.
80. Zamanian-Daryoush, M., J. T. Marques, M. P. Gantier, M. A. Behlke, M. John, P. Rayman, J. Finke, and B. R. Williams. 2008. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon Cytokine Res. 28:221-233. (Pubitemid 351591447)
81. Zhang, R., Z. Guo, J. Lu, J. Meng, C. Zhou, X. Zhan, B. Huang, X. Yu, M. Huang, X. Pan, W. Ling, X. Chen, Z. Wan, H. Zheng, X. Yan, Y. Wang, Y. Ran, X. Liu, J. Ma, C. Wang, and B. Zhang. 2003. Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. Chin Med. J. (English Ed.) 116:1262-1264.
82. Zhang, W., H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R. F. Lockey, and S. S. Mohapatra. 2005. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11:56-62.
83. Zhao, C. A., X. D. Zhao, H. G. Yu, Y. P. Wu, and X. Q. Yang. 2003. Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNAzyme. Zhonghua Er Ke Za Zhi 41:594-597. (In Chinese.)
84. Zhou, J., X. Q. Yang, Y. Y. Xie, X. D. Zhao, L. P. Jiang, L. J. Wang, and Y. X. Cui. 2007. Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice. Virus Res. 130:241-248. (Pubitemid 350051109)
85. Zlateva, K. T., P. Lemey, E. Moes, A. M. Vandamme, and M. Van Ranst. 2005. Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J. Virol. 79:9157-9167. (Pubitemid 40934827)
86. Zlateva, K. T., P. Lemey, A. M. Vandamme, and M. Van Ranst. 2004. Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup A: positively selected sites in the attachment G glycoprotein. J. Virol. 78:4675-4683.